ADVERTISEMENT

Richter Gedeon strikes $408 million deal to acquire Australian Mayne Pharma

Richter Gedeon
Richter Gedeon corporate photo

Hungarian pharmaceutical group Gedeon Richter has agreed to acquire Australia's Mayne Pharma for approximately AUD 604 million ($408 million), offering shareholders almost twice the company's previous closing share price.

The proposed acquisition would expand Richter's presence in the US pharmaceutical market, particularly in women's health and dermatology, with completion targeted for March 2027.

Under the agreement, Richter will pay AUD 6.40 in cash for each Mayne Pharma share, valuing the Australian company's equity at approximately AUD 604 million. The offer represents a 99.4% premium to Mayne Pharma's closing share price on the announcement date and a 124% premium to its 30-day volume-weighted average price.

Richter targets a larger share of the US women's health market

Mayne Pharma's US business focuses on women's health and dermatology, with an established commercial distribution network. Its portfolio includes an innovative combined oral contraceptive based on estetrol, a product category already central to Richter's women's healthcare strategy.

The Australian company's DistributeRx platform, launched in March 2026, has also expanded patient access to its pharmaceutical products in the United States.

Egis opens Hungary’s largest pharmaceutical warehouse near Budapest

László Kovács, Richter's deputy CEO, said Mayne Pharma's existing product portfolio and commercial infrastructure would provide a foundation for introducing additional treatments to US patients across several therapeutic areas.

A separate AUD 55.5 million divestment must close first

The acquisition is conditional on Mayne Pharma completing the sale of its international business to Evaris Pharma, announced on November 6 for AUD 55.5 million.

That divestment would leave Mayne Pharma focused on the United States, with women's health, dermatology and the DistributeRx platform forming the core of its operations.

The international business generated AUD 70.7 million in revenue during Mayne Pharma's 2026 financial year, according to the company's investor presentation. Its agreed sale price is equivalent to approximately 0.79 times annual revenue.

Mayne Pharma shareholders to vote in January 2027

Mayne Pharma's board has unanimously recommended the Richter transaction, provided no superior offer emerges and an independent expert concludes that the proposal is in shareholders' best interests.

The Australian company's three largest shareholders, representing 22.14% of its issued shares, have indicated their intention to support the deal, subject to the stated conditions. A shareholder meeting is expected in late January 2027, with court proceedings and implementation scheduled for March.

The proposed acquisition follows the termination of an earlier agreement involving US pharmaceutical company Cosette in December 2025. Cosette's previous AUD 672 million takeover proposal had encountered regulatory opposition in Australia.

Richter reported €2.3 billion in revenue in 2025

Founded in Hungary in 1901, Gedeon Richter operates in approximately 50 countries, with activities spanning pharmaceutical research, manufacturing and commercial distribution.

The company reported revenue of approximately €2.3 billion in 2025 and had a market capitalisation of around €4.8 billion at the time of the Mayne Pharma announcement.


ADVERTISEMENT